Relationship between antifungal resistance of fluconazole resistant Candida albicans and mutations in ERG11 gene

Chinese Medical Journal

Volumn 123, Issue 5, 2010, Pages 544-548

  Feng, Li Juan ^a   Wan, Zhe ^a   Wang, Xiao Hong ^a   Li, Ruo Yu ^a   Liu, Wei ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Candida albicans; Drug resistance; Erg11 gene; Fluconazole

Indexed keywords

FLUCONAZOLE; METHYLTRANSFERASE; PROTEIN ERG11; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA ALBICANS; DNA SEQUENCE; FUNGAL STRAIN; FUNGUS ISOLATION; GENE IDENTIFICATION; GENE MUTATION; NONHUMAN; POLYMERASE CHAIN REACTION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; FUNGAL PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 77949344512     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.05.007     Document Type: Article

References (30)

1. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother 1995; 35: 103-114.
2. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39: 1-8.
3. Vuffray A, Durussel C, Boerlin P, Boerlin-Petzold F, Bille J, Glauser MP, et al. Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients. AIDS 1994; 8: 708-709.
4. Sanglard D, Ischer F, Koymans L, Bille J. Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob Agents Chemother 1998; 42: 241-253.
5. Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, et al. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 1999; 145: 2701-2713.
6. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
7. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 2nd ed. M27-A2. National Committee for Clinical Laboratory Standards, WAYNE, PA. 2002.
8. Franz R, Kelly SL, Lamb DC, Kelly DE, Ruhnke M, Morschhauser J. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 1998; 42: 3065-3072.
9. Loffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H. Molecular analysis of cyp51 from fluconazole resistant Candida albicans strains. FEMS Microbiol Lett 1997; 151: 263-268.
10. Perea S, Lopez-Ribot JL, Kirkpatrick WR, McAtee RK, Santillan RA, Martinez M, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684.
11. Vanden Bossche H, Marichal P, Gorrens J, Bellens D, Moereels H, Janssen PA. Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinity for azole antifungals. Biochem Soc Trans 1990; 18: 56-59.
12. White TC. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 1997; 41: 1482-1487.
13. White TC. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob Agents Chemother 1997; 41: 1488-1494.
14. Sanglard D, Ischer F, Monod M, Bille J. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob Agents Chemother 1996; 40: 2300-2305.
15. Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 1995; 39: 2378-2386.
16. Ghannoum MA, Rex JH, Galgiani JN. Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome. J Clin Microbiol 1996; 34: 489-495.
17. Maebashi K, Kudoh M, Nishiyama Y, Makimura K. Uchida K. Mori T, et al. A novel mechanism of fluconazole resistance associated with fluconazole sequestration in Candida albicans isolates from a myelofibrosis patient. Microbiol Immunol 2002; 46: 317-326.
18. Goldman GH, da Silva Ferreira ME, dos Reis Marques E, Savoldi M, Perlin D, Park S, et al. Evaluation of fluconazole resistance mechanisms in Candida albicans clinical isolates from HIV-infected patients in Brazil. Diagn Microbiol Infect Dis 2004; 50: 25-32.
19. Kakeya H, Miyazaki Y, Miyazaki H, Nyswaner K, Grimberg B, Bennett JE. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob Agents Chemother 2000; 44: 2985-2990.
20. Lamb DC, Kelly DE, White TC, Kelly SL. The R467K amino acid substitution in Candida albicans sterol 14alpha-demethylase causes drug resistance through reduced affinity. Antimicrob Agents Chemother 2000; 44: 63-67.
21. Kelly SL, Lamb DC, Kelly DE. Y132H substitution in Candida albicans sterol 14alpha-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol Lett 1999; 180: 171-175.
22. Kelly SL, Lamb DC, Loeffler J, Einsele H, Kelly DE. The G464S amino acid substitution in Candida albicans sterol 14alpha-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem Biophys Res Commun 1999; 262: 174-179.
23. Löffler J, Kelly SL, Hebart H, Schumacher U, Lass-Florl C, Einsele H. Molecular analysis of cyp51 from fluconazole resistant Candida albicans strains. FEMS Microbiol Lett 1997; 151: 263-268.
24. Kamai Y, Maebashi K, Kudoh M, Makimura K, Naka W, Uchida K, et al. Characterization of mechanisms of fluconazole resistance in a Candida albicans isolate from a Japanese patient with chronic mucocutaneous candidiasis. Microbiol Immunol 2004; 48: 937-943.
25. White TC, Holleman S, Dy F, Mirels LF, Stevens DA. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother 2002; 46: 1704-1713.
26. Maebashi K KM, Nishiyama Y, Makimura K, Makimura K, Kamai Y, Uchida K, et al. Proliferation of intracellular structure corresponding to reduced affinity of fluconazole for cytochrome P-450 in two low-susceptibility strains of Candida albicans isolated from a Japanese AIDS patient. Microbiol Immunol 2003; 47: 117-124.
27. Cernicka J, Subik J. Resistance mechanisms in fluconazole resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents 2006; 27: 403-408.
28. Ji HT, Zhang WN, Zhou YJ, Zhu J, Lu JG. A Three-dimensional Model of Lanosterol 14alpha-demethylase of Candida albicans. Acta Biochimica et Biophysica Sinica (Chin) 1998; 30: 585-592.
29. Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 2004; 48: 568-574.
30. Ji H, Zhang W, Zhou Y, Zhang M. Zhu J, Song Y, et al. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals. J Med Chem 2000; 43: 2493-2505.